Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Zanubrutinib

Catalog No: tcsc0021869

Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg

Size: 50mg

Specifications

CAS No:
1691249-45-2

Formula:
$C_{27}H_{29}N_5O_3$

Pathway:
Protein Tyrosine Kinase/RTK

Target:
Btk

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 56.75 mg/mL (120.35 mM); Ethanol :

Alternative Names:
BGB-3111

Observed Molecular Weight:
471.55

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

Zanubrutinib is a selective **Bruton tyrosine kinase** (**BTK**) inhibitor.

IC50 & Target: BTK[1]

In Vitro: Zanubrutinib (BGB-3111) is a selective Bruton tyrosine kinase (BTK) inhibitor. In both biochemical and cellular assays, Zanubrutinib demonstrates nanomolar BTK inhibition activity. In several MCL and DLBCL cell lines, Zanubrutinib inhibits BCR aggregation-triggered BTK autophosphorylation, blocks downstream PLC-γ2 signaling, and potently inhibits cell proliferation. In comparison with ibrutinib, Zanubrutinib shows much more restricted off-target activities against a panel of kinases, including ITK[1].

In Vivo: Zanubrutinib (BGB-3111) induces dose-dependent anti-tumor effects against REC-1 MCL xenografts engrafted either subcutaneously or systemically via tail vein injection in mice. In the subcutaneous xenografts, Zanubrutinib at 2.5 mg/kg BID shows similar activity as ibrutinib at 50 mg/kg QD. In the systemic model, the median survival of Zanubrutinib 25 mg/kg BID group is significantly longer than those of both ibrutinib 50 mg/kg QD and BID groups. In an ABC-subtype DLBCL (TMD-8) subcutaneous xenograft model, Zanubrutinib also demonstrates better anti-tumor activity than ibrutinib. Preliminary 14-day toxicity study in rats shows that Zanubrutinib is very well tolerated and maximal tolerate dose (MTD) is not reached when it is dosed up to 250 mg/kg/day [1].